small molecule

ABSORICA LD

ISOTRETINOIN

Loss of exclusivityAugust 2035latest FDA-listed patent expiry
CompanySUN PHARMACEUTICAL INDUSTRIES LTD

Drug detail

Brand nameABSORICA LD
Active ingredientISOTRETINOIN
Strength28MG
Dosage formCAPSULE
RouteORAL
ModalitySmall molecule
FDA approvalNovember 2019
Marketing statusDISCN

Listed patents

PatentExpiresType
9700535August 2035product
9750711May 2035product

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

ABSORICA LD patent cliff — loss of exclusivity August 2035 | CliffBio